BR112012011332A2 - agentes direcionados para gadd45beta - Google Patents

agentes direcionados para gadd45beta

Info

Publication number
BR112012011332A2
BR112012011332A2 BR112012011332A BR112012011332A BR112012011332A2 BR 112012011332 A2 BR112012011332 A2 BR 112012011332A2 BR 112012011332 A BR112012011332 A BR 112012011332A BR 112012011332 A BR112012011332 A BR 112012011332A BR 112012011332 A2 BR112012011332 A2 BR 112012011332A2
Authority
BR
Brazil
Prior art keywords
gadd45beta
agents directed
groups
tetrapeptide
tripeptide
Prior art date
Application number
BR112012011332A
Other languages
English (en)
Other versions
BR112012011332B1 (pt
Inventor
Albert Andrzej Jaxa-Chamiec
Catherine Jane Tralau-Stewart
Caroline Minli Rachel Low
Guido Franzoso
Laura Tornatore
Menotti Ruvo
Simona Maria Monti
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of BR112012011332A2 publication Critical patent/BR112012011332A2/pt
Publication of BR112012011332B1 publication Critical patent/BR112012011332B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

agentes direcionados para gadd45beta compostos à base de grupos tetrapeptídicos, tripeptídicos e dipeptídicos e grupos peptóides correespondentes. metódos correlatos e composições farmacêuticas para uso no tratamento de câncer , doenças inflamatórias e de outros transtornos.
BR112012011332-1A 2009-10-22 2010-10-22 Agentes direcionados para gadd45beta BR112012011332B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0918579.4A GB0918579D0 (en) 2009-10-22 2009-10-22 Gadd45beta targeting agents
GB0918579.4 2009-10-22
PCT/GB2010/001970 WO2011048390A2 (en) 2009-10-22 2010-10-22 Gadd45beta targeting agents

Publications (2)

Publication Number Publication Date
BR112012011332A2 true BR112012011332A2 (pt) 2016-11-22
BR112012011332B1 BR112012011332B1 (pt) 2022-07-05

Family

ID=41426579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011332-1A BR112012011332B1 (pt) 2009-10-22 2010-10-22 Agentes direcionados para gadd45beta

Country Status (14)

Country Link
US (2) US8993717B2 (pt)
EP (2) EP2491051A2 (pt)
JP (2) JP5961113B2 (pt)
KR (1) KR20120099440A (pt)
CN (1) CN102741269B (pt)
AU (1) AU2010309594B2 (pt)
BR (1) BR112012011332B1 (pt)
CA (2) CA2778236A1 (pt)
GB (1) GB0918579D0 (pt)
IL (1) IL219325B (pt)
IN (1) IN2012DN03310A (pt)
MX (1) MX357801B (pt)
RU (2) RU2016102083A (pt)
WO (1) WO2011048390A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
GB201107118D0 (en) * 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
KR101745766B1 (ko) * 2011-10-14 2017-06-09 서울대학교산학협력단 펩타이드 나노구조체 및 그 제조 방법
EP3248609B1 (en) 2011-10-28 2019-10-16 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
WO2013142376A1 (en) * 2012-03-19 2013-09-26 Aposignal Bioscience Llc Composition and methods for cell modulation
CN104817616A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd02及其制备方法和应用
CN104817618B (zh) * 2014-01-30 2018-07-03 陈光健 寡肽cd01及其制备方法和应用
GB201414542D0 (en) * 2014-08-15 2014-10-01 Imp Innovations Ltd Novel therapy
CN111574585B (zh) * 2019-01-30 2021-10-01 浙江省医学科学院 一种鳕鱼皮寡肽及其分离纯化方法和应用
RU2716258C1 (ru) * 2019-07-30 2020-03-11 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Пептидный антагонист нмда-рецептора
KR102417496B1 (ko) * 2019-11-29 2022-07-06 (주)수파드엘릭사 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
WO2021194228A1 (ko) * 2020-03-23 2021-09-30 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
KR102348728B1 (ko) * 2020-03-23 2022-01-12 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
US20230159587A1 (en) * 2021-03-22 2023-05-25 L-Base Co., Ltd. Pharmaceutical composition for preventing or treating cancer
WO2022203219A1 (ko) * 2021-03-22 2022-09-29 주식회사 엘베이스 암의 예방 또는 치료용 약학적 조성물
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
IT202100023357A1 (it) * 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
KR102494749B1 (ko) * 2021-09-17 2023-02-06 주식회사 엘베이스 암 치료용 cage 저해제에 대한 반응자 특성화 방법
WO2023043269A1 (ko) * 2021-09-17 2023-03-23 주식회사 엘베이스 면역반응을 조절하기 위한 약학적 조성물
WO2023043261A1 (ko) * 2021-09-17 2023-03-23 주식회사 엘베이스 항암제의 항암 효과 증진용 약학적 조성물
CN116350746B (zh) * 2023-05-16 2024-03-22 海口桥水联合科技有限责任公司 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
HU187461B (en) * 1981-10-22 1986-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing n-nitrozo-n-bracket-beta-chloroethyl-bracket closed-carbamoyl-peptides of citostatic activity
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
DE3813989A1 (de) * 1987-04-29 1988-11-10 Hoechst Ag Peptide mit phospholipase a(pfeil abwaerts)2(pfeil abwaerts)-hemmender wirkung
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US20030162223A1 (en) 1999-10-22 2003-08-28 Lowery David E. Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN1535264A (zh) * 2001-05-15 2004-10-06 ������ҩ��ʽ���� 精氨酸衍生物
DE60229883D1 (de) * 2001-07-13 2008-12-24 Cms Peptides Patent Holding Co Biologisch aktive peptide
EP1453467A4 (en) 2001-10-02 2008-01-09 Univ Chicago METHODS AND COMPOSITIONS FOR MODULATING APOPTOSIS
US7354898B2 (en) * 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
AU2003259795A1 (en) 2002-08-19 2004-03-03 Yun Yen Treatment of liver deseases
EP1615954A2 (en) 2003-04-22 2006-01-18 Avanir Pharmaceuticals Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
ES2412483T3 (es) * 2005-01-13 2013-07-11 University Of Wollongong Derivados antibióticos de binaftilo
ES2378242T3 (es) * 2005-02-09 2012-04-10 Helix Biomedix, Inc. Hexapéptidos antimicrobianos
US7919468B2 (en) * 2005-04-07 2011-04-05 Centre National De La Recherche Scientifique (C.N.R.S.) Compounds useful as modulators of the proteasome activity
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2007037297A1 (ja) * 2005-09-29 2007-04-05 Maruha Corporation 成人病の予防及び治療に有効な組成物
JP2007217358A (ja) * 2006-02-17 2007-08-30 Nippon Meat Packers Inc 抗酸化性ペプチド
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN101153053B (zh) * 2006-09-28 2012-02-01 中国医学科学院药物研究所 骨生肽、其制备方法和其药物组合物与用途
EP1964560A1 (en) 2007-02-28 2008-09-03 Helmholtz-Zentrum für Infektionsforschung GmbH Use of inhibitors of the degradation of p27 for the treatment of cancer
WO2009099677A2 (en) 2008-02-08 2009-08-13 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
EP2390662A1 (en) 2010-05-27 2011-11-30 Erasmus University Medical Center Rotterdam Molecular classification of multiple myeloma

Also Published As

Publication number Publication date
WO2011048390A2 (en) 2011-04-28
KR20120099440A (ko) 2012-09-10
AU2010309594A1 (en) 2012-05-17
US20150368294A1 (en) 2015-12-24
CA2778236A1 (en) 2011-04-28
JP2013508346A (ja) 2013-03-07
US20120277164A1 (en) 2012-11-01
GB0918579D0 (en) 2009-12-09
RU2012120905A (ru) 2013-11-27
JP2016166211A (ja) 2016-09-15
IL219325B (en) 2019-02-28
BR112012011332B1 (pt) 2022-07-05
IL219325A0 (en) 2012-06-28
MX357801B (es) 2018-07-25
EP3178836A1 (en) 2017-06-14
JP5961113B2 (ja) 2016-08-02
WO2011048390A3 (en) 2011-11-03
RU2577311C2 (ru) 2016-03-20
RU2016102083A (ru) 2018-11-20
EP3178836B1 (en) 2019-12-25
IN2012DN03310A (pt) 2015-10-23
CA3034860A1 (en) 2011-04-28
AU2010309594B2 (en) 2016-01-07
CN102741269A (zh) 2012-10-17
MX2012004755A (es) 2012-11-22
US9518083B2 (en) 2016-12-13
CN102741269B (zh) 2017-08-29
EP2491051A2 (en) 2012-08-29
US8993717B2 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
BR112012011332A2 (pt) agentes direcionados para gadd45beta
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
ECSP077238A (es) Composiciones para entrega de drogas altamente solubles en agua
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
DOP2011000274A (es) Proteinas de union a il-17
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
PH12014500053A1 (en) Proteasome inhibitors
CL2016001405A1 (es) A peptide mixture
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
CL2008001540A1 (es) Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008000348A1 (es) Compuestos derivados de carboxamida, inhibidores de la actividad de la proteina quinasa b; composicion farmaceutica; proceso para prepararla; y uso en el tratamiento de enfermedades tales como cancer y artritis.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
EA201270722A1 (ru) Формы рифаксимина и их применение
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: IP2IPO INNOVATIONS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: IP2IPO INNOVATIONS LIMITED (GB)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: IMPERIAL INNOVATIONS LTD (GB)

Free format text: ANULADA A PUBLICACAO CODIGO 25.7 NA RPI NO 2649 DE 13/10/2021 POR TER SIDO INDEVIDA.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: IMPERIAL INNOVATIONS LTD (GB)

Free format text: ANULADA A PUBLICACAO CODIGO 25.4 NA RPI NO 2648 DE 05/10/2021 POR TER SIDO INDEVIDA.

B25D Requested change of name of applicant approved

Owner name: IP2IPO INNOVATIONS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: IP2IPO INNOVATIONS LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.